GSK has received the FDA approval for its HIV two-drug combo in a single tablet called Juluca. It is a fixed-dose tablet containing two previously approved (active ingredients) drugs, dolutegravir from GSK and rilpivirine from J&J, and will be given to patients who have been on an anti-retroviral therapy for at least six months.
22 Nov 2017
When less is more
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
When less is more
GSK plc (GSK:LON) | 1,653 33.1 0.1% | Mkt Cap: 68,515m
- Published:
22 Nov 2017 -
Author:
Kamla Singh -
Pages:
3
GSK has received the FDA approval for its HIV two-drug combo in a single tablet called Juluca. It is a fixed-dose tablet containing two previously approved (active ingredients) drugs, dolutegravir from GSK and rilpivirine from J&J, and will be given to patients who have been on an anti-retroviral therapy for at least six months.